Thomas Faustmann Global Medical Head Women’s Health: What will it take to develop disease-modifying therapies for PMOS/PCOS?
Moving beyond symptom management towards disease-modifying therapies requires studies that connect clear biological mechanisms with meaningful clinical outcomes.
In this short video, Thomas Faustmann of Gedeon Richter shares an industry perspective on what is needed: well-defined biological pathways, targeted interventions and measurable improvements in core PMOS/PCOS outcomes.
Watch the video to hear Thomas’s perspective.


